Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 87 clinical trials
Featured trial
Phase 2, Open-Label, Multicenter Study of INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

The purpose of this study is to determine the safety, tolerability, efficacy, PK and pharmacodynamics of INCAGN01876 when given in combination with retifanlimab. The study will consist of 2 parts: a safety lead-in part (Part 1) followed by a dose expansion part (Part 2).

  • 0 views
  • 22 Sep, 2022
Featured trial
Study of HB-200 alone and with pembrolizumab for patients with Recurrent/ Metastatic HPV 16+ Head and Neck and other Cancers

HB-201 and HB-202 are study drugs which are designed to train the body to recognize and fight substances found in HPV16+ cancer. This trial studies the safety and anti-cancer effect of HB-201 and HB-202 in people. HPV is a group of more than 200 related viruses, each given a number. HPV …

head and neck cancer
carcinoma
neck cancer
cancer
measurable disease
  • 0 views
  • 27 May, 2022
  • 16 locations
Laparoscopic Robot-assisted Pelvic Exenteration for Pelvic Primary and Recurrent Cancers

The Radium Hospital Oslo University Hospital Estimated date of first patient enrolled: 3rd quarter 2021 Anticipated recruitment period: 4 years Estimated date of last patient completed: 4th quarter 2025 Locally advanced pelvic cancer that requires total pelvic exenteration Expected study-specific follow-up period per patient: 5 years according to standard follow-up …

  • 0 views
  • 23 Mar, 2022
68Ga-NODAGA-RGD PET/ CT for Tumoral Neoangiogenesis

) is indicated for initial extension evaluation or suspicion of recurrent tumor.

  • 0 views
  • 05 Jul, 2022
  • 1 location
Study of E7386 in Participants With Selected Advanced Neoplasms

This study will be conducted to assess the safety/tolerability profile of E7386 as a single agent administered orally in participants with selected advanced or recurrent neoplasms and to

  • 54 views
  • 29 Jan, 2022
  • 3 locations
Salvage Systemic Therapy With or Without Stereotactic Ablative Radiotherapy for Recurrent Ovarian Cancer (SABR-ROC)

therapy is often difficult because recurrent tumors do not respond uniformly to systemic therapy. In the 1980~1990s, whole abdomen irradiation had been tried and faded out owing to many side

  • 0 views
  • 25 Jul, 2022
  • 1 location
Study of the of the Safety and Tolerability of TT-00434 in Patients With Advanced Solid Tumors

This is a phase I study of the safety, tolerability, pharmacokinetics profile, and preliminary efficacy of TT-00434 in patients with advanced solid tumors.

  • 0 views
  • 02 Nov, 2021
  • 3 locations
GD2/CD56 Bi-specific CAR-T Cell Therapy

The purpose of this clinical trial is to assess the feasibility, safety and efficacy of anti-GD2/CD56 bi-specific CAR-T cell therapy in patients with GD2 and/or CD56 positive cancer. Another goal of the study is to learn more about the function of the anti-GD2/CD56 bi-specific CAR-T cells and their persistency in …

  • 0 views
  • 14 Jul, 2022
  • 1 location
First-in-human Phase I to Evaluate PEP-010 as Single Agent and in Combination With Paclitaxel (CleverPeptide)

This is an open-label, non-controlled, multicenter, dose escalation, first-in-human phase I clinical trial with an expansion phase designed to assess the safety, tolerability, PK and PD parameters, and preliminary antitumor activity of intravenous dosing of PEP-010 as single agent and in combination with paclitaxel. PEP-010 will be administered as single …

  • 0 views
  • 31 May, 2021
  • 3 locations
GD2/CD70 Bi-specific CAR-T Cell Therapy

The purpose of this study is to assess the feasibility, safety and efficacy of GD2/CD70 bi-specific CAR-T cell therapy in patients with GD2 and/or CD70 positive tumor. Another goal of the study is to learn more about the function of the GD2/CD70 bi-specific CAR-T cells and their persistency in patients.

  • 0 views
  • 10 Jul, 2022
  • 1 location